SK Biopharmaceuticals' acquisition of the next-generation epilepsy drug candidate 'Opakalim (BHV-7000)' is seen as an opportunity to expand its existing business structure centered on Xcopri, with securities firms raising their target prices to reflect the value of the new drug pipeline.

■ Target Price Raised from 150,000 to 160,000 Won... 'Buy' Rating Maintained

On the 27th, Hana Securities raised its target price for SK Biopharmaceuticals from 150,000 won to 160,000 won and maintained its 'Buy' investment opinion. According to search results, the target price increase report was confirmed to have been written by Hana Securities, not Daol Investment & Securities.

■ Up to $795 Million... Exclusive Worldwide Licensing Deal for Kv7 Ion Channel Platform

SK Biopharmaceuticals signed a contract the previous day securing an exclusive worldwide license from Biohaven for the Kv7 ion channel platform, including Opakalim. The total deal size is up to $795 million, approximately 1.1 trillion won.

Opakalim is an oral epilepsy treatment candidate that selectively activates Kv7.2/Kv7.3 potassium channels to suppress excessive neuronal excitation. Phase 2/3 clinical trials are currently underway in patients with focal onset seizures, with topline results from the RISE3 trial expected in the second half of this year. If development proceeds smoothly, SK Biopharmaceuticals aims to launch the drug in the United States as early as 2029.

■ Synergy with Xcopri... Preparing for 2032 Patent Expiration

This deal goes beyond simply acquiring a single asset in Opakalim. SK Biopharmaceuticals also secured rights to the Kv7 discovery platform and related compound series, expanding its foundation for developing follow-on new drugs.

In particular, synergy with its existing flagship product Xcopri is considered key. SK Biopharmaceuticals already sells Xcopri directly in the United States and has built a local sales network. If Opakalim is commercialized, the company can leverage its existing sales infrastructure, reducing the burden of building an additional large-scale sales organization — a significant advantage.

The acquisition of Opakalim is also meaningful given that the U.S. substance patent for Xcopri is set to expire in 2032. Hana Securities evaluated that the introduction of Opakalim is a strategic choice that prepares a growth driver beyond Xcopri while strengthening the company's epilepsy treatment portfolio.

■ Key Remaining Factors: Clinical Results and Competitive Landscape

However, as Opakalim is still a clinical-stage candidate, future clinical results and approval status are expected to be key variables in determining enterprise value. The competitive landscape with other Kv7-class therapies also needs to be examined during the commercialization process.

[Stock prices may experience heightened volatility depending on corporate performance, industry conditions, merger terms, and market supply and demand. Securities firms' analyses and forecasts may differ from actual future results and do not guarantee returns on specific stocks. Before making investment decisions, it is necessary to comprehensively review the company's official disclosures, financial condition, and business progress. This article is not intended to recommend the purchase or sale of any specific stock. This article was written with AI assistance.]